Form 4 Filing for Foghorn Therapeutics Inc.

This filing details transactions by Adrian Gottschalk, CEO and Director of Foghorn Therapeutics Inc. (FHTX). On April 9, 2026, 47,497 shares of Common Stock were transferred from the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust (2023 GRAT) to the Adrian H. Gottschalk Living Trust. On April 10, 2026, an additional 59,208 shares were transferred from the Adrian H. Gottschalk 2025 Grantor Retained Annuity Trust (2025 GRAT) to the Living Trust. All these transactions were non-sale acquisitions or dispositions (Code G) with no price reported, indicating they were likely internal trust transfers. Following these transactions, the total shares held in the Living Trust amount to 270,912.